Claims for Patent: 9,771,432

Summary for Patent: 9,771,432

Title:	Conjugation methods
Abstract:	This invention describes a method of conjugating a cell binding agent such as an antibody with an effector group (e.g., a cytotoxic agent) or a reporter group (e.g., a radionuclide), whereby the reporter or effector group is first reacted with a bifunctional linker and the mixture is then used without purification for the conjugation reaction with the cell binding agent. The method described in this invention is advantageous for preparation of stably-linked conjugates of cell binding agents, such as antibodies with effector or reporter groups. This conjugation method provides in high yields conjugates of high purity and homogeneity that are without inter-chain cross-linking and inactivated linker residues.
Inventor(s):	Kellogg; Brenda A. (Medford, MA), Singh; Rajeeva (Framingham, MA), Chari; Ravi V. J. (Newton, MA)
Assignee:	IMMUNOGEN, INC. (Waltham, MA)
Application Number:	15/167,476
Patent Claims:	1. A process for preparing a purified conjugate in a solution, wherein the conjugate comprises an effector or a reporter molecule comprising a thiol group linked to a cell binding agent, the process comprising the steps of: (a) contacting the effector or the reporter molecule comprising a thiol group with a bifunctional linker reagent represented by one of the following formulas ##STR00009## to covalently attach the linker to the effector or the reporter molecule and thereby prepare an unpurified first mixture comprising the effector or the reporter molecule having linkers bound thereto, (b) mixing the unpurified first mixture comprising the effector or the reporter molecule having linkers bound thereto with a cell binding agent at a pH of about 5, to form an unpurified second mixture, (c) conjugating the cell binding agent to the effector or the reporter molecule having linkers bound thereto by increasing the pH of the unpurified second mixture to about 6.5 to about 8.5 to prepare a third mixture, and (d) subjecting the third mixture to tangential flow filtration, dialysis, gel filtration, adsorptive chromatography, selective precipitation or a combination thereof to thereby prepare the purified conjugate. 2. The process of claim 1, wherein in step (c) the pH is increased to about 6.5. 3. The process of claim 1, wherein the third mixture in step (c) is substantially free of undesired cross-linked, hydrolyzed species formed due to intra-molecular or inter-molecular reactions. 4. The process of claim 1, wherein the effector or the reporter molecule is a cytotoxic agent. 5. The process of claim 4, wherein the cytotoxic agent is maytansinoids, taxanes, CC1065, or analogs thereof. 6. The process of claim 4, wherein the cytotoxic agent is a maytansinoid. 7. The process of claim 6, wherein the maytansinoid is DM1. 8. The process of claim 6, wherein the maytansinoid is DM4. 9. The process of claim 1, wherein the cell binding agent is interferons, interleukin 2 (IL-2), interleukin 3 (IL-3), interleukin 4 (IL-4), interleukin 6 (IL-6), insulin, EGF, TGF-.alpha., FGF, G-CSF, VEGF, MCSF, GM-CSF, transferrin, or antibodies. 10. The process of claim 9, wherein the cell binding agent is an antibody. 11. The process of claim 10, wherein the antibody is a monoclonal antibody. 12. The process of claim 10, wherein the antibody is a human or a humanized monoclonal antibody. 13. The process of claim 10, wherein the antibody is MY9, anti-B4, C242, or an antibody that binds to an antigen selected from the group consisting of EpCAM, CD2, CD3, CD4, CD5, CD6, CD11, CD19, CD20, CD22, CD26, CD30, CD33, CD37, CD38, CD40, CD44, CD56, CD79, CD105, CD138, EphA receptors, EphB receptors, EGFR, EGFRvIII, HER2, HER3, mesothelin, cripto, alpha.sub.vbeta.sub.3, alpha.sub.vbeta.sub.5, and alpha.sub.vbeta.sub.6 integrin. 14. The process of claim 12, wherein the human or the humanized antibody is huMy9-6, huB4, huC242, huN901, DS6, CNTO 95, B-B4, trastuzumab, pertuzumab, bivatuzumab, sibrotuzumab, rituximab, or a human or humanized antibody that binds to an antigen selected from the group consisting of EphA2 receptor, CD38, and IGF-IR. 15. The process of claim 1, wherein the reporter molecule is a radioisotope. 16. The process of claim 6, wherein an excess of maytansinoid relative to the bifunctional linker reagent is used. 17. The process of claim 6, wherein the process further comprises the step of quenching the excess maytansinoid in the unpurified first, second, or third mixture with a quenching reagent between steps (a) and (d). 18. The process of claim 17, wherein the quenching reagent is selected from the group consisting of 4-maleimidobutyric acid, 3-maleimidopropionic acid, N-ethylmaleimide, iodoacetamide, and iodoacetamidopropionic acid. 19. The process of claim 1, wherein the bifunctional linker reagent is represented by the following formula: ##STR00010## 20. The process of claim 1, wherein in step (c) the pH is increased to about 7.0. 21. The process of claim 1, wherein in step (c) the pH is increased to about 7.5. 22. The process of claim 1, wherein in step (c) the pH is increased to about 8.0.

Details for Patent 9,771,432

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997		2029-06-03
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002		2029-06-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	09/25/1998		2029-06-03
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	02/10/2017		2029-06-03
Genentech, Inc.	PERJETA	pertuzumab	Injection	125409	06/08/2012		2029-06-03